A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess theEfficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis – The ASPEN Study

Project: Research

Project Details

Project Description

NMA HREC Reference Number: CALHN HREC ref Q20200901
NMA SSA Reference Number: SSA/68385/MonH-2021-247722(v1)
Monash Health Reference: RES-21-0000-031X
Effective start/end date15/03/2114/03/26


  • clinical trial
  • phase 3 study
  • treatment efficacy
  • treatment safety
  • bronchiectasis